FACBC PET/CT for Recurrent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Prostate Cancer
Interventions
DRUG

FACBC

Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan

OTHER

ProstaScinct

ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.

Trial Locations (1)

30322

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

David M. Schuster, MD

OTHER

NCT00562315 - FACBC PET/CT for Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter